Please take a moment to review the important CE information on this page.

To earn free CE credit for watching this program, you must complete the online CE test and evaluation. You must be registered and signed-in in order to take the test online. Upon successful completion of the test and the evaluation, you will be asked to select your professional category and will be able to print the appropriate credit certificate right from your computer. You must answer a minimum of 8 out of 10 questions correctly in order to earn CE credit.

Before taking this CE exam for credit, please have a printer connected to your computer. You will also need Adobe Flash Player 9. If you have a previous version, please click HERE for a free upgrade to Adobe Flash Player 9.

If you would like to download a list of the questions to have with you when you watch the show, click download the CE questions.

Click here for a list of CME Requirements by State.

Metastatic Colon Cancer: The Continuum of Care
is no longer available for CME credit.

Accreditation

Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

NCCN designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

This activity is approved for 1.0 contact hour. National Comprehensive Cancer Network is an approved provider of continuing nursing education by PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Contact NCCN at webcasts@nccn.org.

Program Overview
In response to the burgeoning data regarding patient risk assessment and the selection of therapies, the National Comprehensive Cancer Network (NCCN) has brought together members of the NCCN Colon Cancer Guidelines Panel to discuss the process for development of the NCCN Clinical Practice Guidelines in Oncology™. The program will focus on the evolving data in medical and surgical management of metastatic colon cancer and their application in the current NCCN guidelines, selection of adjuvant and systemic therapy for advanced disease, and sequencing of agents in second- and third-line therapy.

Learning Objectives
At the conclusion of this program, participants should be able to:

• Discuss recent updates made to the NCCN Clinical Practice Guidelines in Oncology™ Colon Cancer
• List current options for metastatic disease
• Describe the use of adjuvant therapy
• Provide the rationale for sequencing of systemic therapy
• Differentiate between management strategies for patients with good versus poor performance status

Target Audience
This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.

Faculty Disclosure Information
All faculty participating in NCCN continuing education activities are expected to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME's and ANCC's Standards for Commercial Support.

The speaker(s) listed below have disclosed that they have financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the activity:

Al B. Benson III, M.D.

• Has served as a consultant for Amgen, Bristol-Myers Squibb, Genentech, ImClone, Pfizer, Roche, and sanofi-aventis.
• Has received grant/research support from Amgen, Bristol-Myers Squibb, Genentech, ImClone, Pfizer, Roche, and sanofi-aventis.

Paul F. Engstrom, M.D.

• Has no relevant financial relationships to disclose.

Leonard Saltz, M.D.

• Has served as a principal investigator for Amgen, Bristol-Myers Squibb, Genentech, ImClone, Merck, Pfizer, and Roche.
• Has served as a consultant for Genentech, Merck, and YM BioSciences.

All speakers have indicated that their presentations will include discussion of investigational or unlabeled uses of commercial products.

Commercial Support
Supported by educational grants from Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Oncology, and Pfizer Inc.